Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517635 | 0.95 | KMT2A (0.73) | KMT2ANR1H4NR4A2PLA2G4BMRGPRX4 | |
| SCHEMBL1665041 | 0.95 | KMT2A (0.73) | KMT2ANR1H4NR4A2PLA2G4BMRGPRX4 | |
| SCHEMBL19665046 | 0.92 | KMT2A (0.73) | KMT2ANR1H4NR4A2PLA2G4BPKM | |
| SCHEMBL2868546 | 0.90 | KMT2A (0.61) | KMT2ANR1H4NR4A2PLA2G4BMRGPRX4 | |
| SCHEMBL2934559 | 0.88 | KMT2A (0.71) | KMT2ANR1H4NR4A2PLA2G4BMRGPRX4 | |
| SCHEMBL10787479 | 0.87 | KMT2A (0.80) | KMT2ANR1H4NR4A2PLA2G4BPKM | |
| SCHEMBL30167982 | 0.87 | KMT2A (0.80) | KMT2ANR1H4NR4A2PLA2G4BPKM | |
| SCHEMBL30432308 | 0.87 | PARP1 (0.59) | KMT2AMEN1TAAR1SMPD1 | |
| SCHEMBL15122761 | 0.86 | KMT2A (0.74) | KMT2ANR1H4NR4A2PLA2G4BMEN1 | |
| SCHEMBL23754680 | 0.86 | KMT2A (0.61) | KMT2ANR1H4NR4A2PLA2G4BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| EP-0801640-B1 | 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME | USA (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6066656-A | IN VITRO METHOD OF ASSAYING FOR ANTIRETROVIRAL ACTIVITY OF A COMPOUND BY MEASURING THE FLUORESCENCE OF A FLUORESCENT COMPOUND, MEASURING THE CHANGE IN FLUORESCENCE OF SAID COMPOUND IN THE PRESENCE OF A RETROVIRAL PROTEASE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0801640-A1 | 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-10-22 | — | — | EP | disclosed |
| WO-1996019437-A9 | 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME | — | 1996-09-06 | — | — | WO | disclosed |
| WO-1996019437-A1 | 2,5-DIAMINO-3,4-DISUBSTITUTED-1,6-DIPHENYLHEXANE ISOSTERES COMPRISING BENZAMIDE, SULFONAMIDE AND ANTHRANILAMIDE SUBUNITS AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | KMT2A 2577/4885NR1H4 2398/4885NR4A2 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.